Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies
about
Epilepsy related to developmental tumors and malformations of cortical developmentFinding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic targetInflammatory mechanisms contribute to the neurological manifestations of tuberous sclerosis complex.Spatiotemporal characterization of mTOR kinase activity following kainic acid induced status epilepticus and analysis of rat brain response to chronic rapamycin treatmentRapamycin attenuates the development of posttraumatic epilepsy in a mouse model of traumatic brain injuryA combination of genetic and biochemical analyses for the diagnosis of PI3K-AKT-mTOR pathway-associated megalencephalyVigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complexGene expression profiling of a hypoxic seizure model of epilepsy suggests a role for mTOR and Wnt signaling in epileptogenesis.A pulse rapamycin therapy for infantile spasms and associated cognitive decline.Bmf upregulation through the AMP-activated protein kinase pathway may protect the brain from seizure-induced cell death.Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorderTransient inhibition of TrkB kinase after status epilepticus prevents development of temporal lobe epilepsy.AMPA receptor antagonist NBQX attenuates later-life epileptic seizures and autistic-like social deficits following neonatal seizuresDiffusion tensor imaging and related techniques in tuberous sclerosis complex: review and future directions.Impairment of kindling development in phospholipase Cγ1 heterozygous mice.Hippocampal granule cell pathology in epilepsy - a possible structural basis for comorbidities of epilepsy?The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway.Mechanisms of epileptogenesis: a convergence on neural circuit dysfunction.Oral everolimus treatment in a preterm infant with multifocal inoperable cardiac rhabdomyoma associated with tuberous sclerosis complex and a structural heart defect.Frontier of epilepsy research - mTOR signaling pathway.Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis.Comparative proteomic approach in rat model of absence epilepsy.Nodule excitability in an animal model of periventricular nodular heterotopia: c-fos activation in organotypic hippocampal slices.Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complexRapamycin down-regulates KCC2 expression and increases seizure susceptibility to convulsants in immature rats.Targeting mTOR as a novel therapeutic strategy for traumatic CNS injuries.Tuberous sclerosis complex: neurological, renal and pulmonary manifestationsRapamycin has age-, treatment paradigm-, and model-specific anticonvulsant effects and modulates neuropeptide Y expression in rats.Impaired autophagy in neurons after disinhibition of mammalian target of rapamycin and its contribution to epileptogenesis.Rapamycin has paradoxical effects on S6 phosphorylation in rats with and without seizures.Rapamycin prevents acute dendritic injury following seizures.Cortical dysplasia: a possible substrate for brain tumors.Antidepressant therapy in epilepsy: can treating the comorbidities affect the underlying disorder?Mammalian target of rapamycin (mTOR) inhibition: potential for antiseizure, antiepileptogenic, and epileptostatic therapy.A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trials.Mammalian target of rapamycin (mTOR) pathways in neurological diseases.Regulation of cell death and epileptogenesis by the mammalian target of rapamycin (mTOR): a double-edged sword?Mechanisms regulating neuronal excitability and seizure development following mTOR pathway hyperactivation.Spatiotemporal progression of ubiquitin-proteasome system inhibition after status epilepticus suggests protective adaptation against hippocampal injury.Infantile spasms: a U.S. consensus report.
P2860
Q26829946-BC1B6123-3646-420E-872F-8A6DFC498385Q27024547-CAEF79C5-1DFB-4B99-B9AA-330F36652F59Q27308042-7E6EE961-A68A-456C-9F62-80CABC6A9884Q27318635-33F9ACC2-7124-445D-BB45-630B889329D2Q27319659-6D569A3F-1E74-465B-A35C-F3EEE54DA50BQ28468603-7973F7FD-58E7-4B49-91C8-C5B5986F2CD5Q28486250-8FE607E6-2121-4F53-91D0-EAA0BCF5C3E4Q28533881-5A6B4BBE-1C30-4FE5-8117-642A260664FCQ30501073-7D321710-0797-4D1C-BBD2-0C88FC6CF428Q30540200-2DDF5643-6D0A-4A16-BB16-AE0FC4B96E87Q30541746-4AB562D4-3D35-4EAE-8CF1-2C0A82FDB370Q30542932-6EADD420-C09C-4F3A-959A-728B2CFA24E7Q30607064-2C7F12AC-56E0-484D-A242-7743DA96FCE2Q30747071-12A6954A-5CD6-4789-B024-C5CA727230D4Q33715730-43A88804-354F-41DC-9D77-8ADCAF8C26B7Q33946570-752DAB57-E3D8-42DD-9634-A9D2B8A2CB88Q34261603-BDB9E32A-C326-44BD-B809-B63872546F41Q34339959-8FE56B74-970D-46D8-AE6F-A0FA6A39886EQ34589342-DBE0954C-00B0-4886-878A-6CDF9922F31BQ35014198-BC7B8373-F91A-4508-8C0C-6272BD1C2843Q35216342-D5FDD7E8-AAFF-48D5-9980-9341B4856004Q35342879-FC509675-B2B5-49E2-8FD0-5389DCB337E6Q35417900-F8606813-82F6-425C-BCA2-D205F6C21E32Q35832641-C4E2293B-CEB0-42F6-9200-D7136A8CE12BQ36110085-74695A70-5AC9-42B8-98C9-94056C55416BQ36140051-1B4D028C-0FF1-4DB4-A657-4763E8272439Q36239644-6B477D37-A2D4-4FCC-B838-16FBC5FCA50EQ36395227-33570D9D-5800-4C55-8A50-831E983D4A44Q36410001-F13B2364-5C56-4A7F-8C0C-C4C7EF57F7F6Q36411217-ECA46F7E-D59F-4DD0-8AFD-C6EEDADF0067Q36639664-C6E255EC-4B8B-4A5D-A8FB-0BC9C9A958C5Q36678551-AF49C767-6E76-4491-9E7A-071D55C9F28CQ36709214-EFD9B723-5376-4C28-B101-2011E54A2FA0Q37419781-93A0298B-EA27-4B8D-B46C-B50DB60971B1Q37419785-610A3A7D-D165-40AB-B48E-6CD2ED2B3B8FQ37432305-D3911C76-9B92-42DC-A59C-D2453E2C05B6Q37603072-38EA5197-9DFD-4A09-A419-BF336F13FBECQ37636466-CAB06156-B7EA-46A2-AD0E-EADC68BF9FCEQ37663375-EF793033-25E1-4507-8BFF-C87AAA527E41Q37770587-D6FD36DD-F827-48EC-92B3-DBB355F58E46
P2860
Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Mammalian target of rapamycin ...... to common acquired epilepsies
@ast
Mammalian target of rapamycin ...... to common acquired epilepsies
@en
type
label
Mammalian target of rapamycin ...... to common acquired epilepsies
@ast
Mammalian target of rapamycin ...... to common acquired epilepsies
@en
prefLabel
Mammalian target of rapamycin ...... to common acquired epilepsies
@ast
Mammalian target of rapamycin ...... to common acquired epilepsies
@en
P2860
P1433
P1476
Mammalian target of rapamycin ...... to common acquired epilepsies
@en
P2093
Michael Wong
P2860
P356
10.1111/J.1528-1167.2009.02341.X
P577
2009-10-08T00:00:00Z